The packet associates this condition with the TERC gene, located on chromosome 3, and lists autosomal dominant inheritance. ClinGen gene-disease validity is not provided in the packet, so the strength of the gene-disease relationship is not certified here, and the molecular mechanism is not described. Recurrence figures, penetrance, and de novo frequency are not certified in this packet.

Diagnostic methods and criteria are not certified in this packet.

The packet lists no FDA-approved treatments and no foundational therapies for this condition. Treatment coverage is not certified in this packet.

Prognosis, natural history, and long-term outcomes are not certified in this packet.

ClinicalTrials.gov records linked to this condition in the packet are numerous, but the listed titles are largely about aplastic anemia, a synonym recorded for the condition, and about related bone marrow failure and transplantation topics. Examples include a sirolimus study in severe aplastic anemia sponsored by the National Heart, Lung, and Blood Institute, a phase 3 trial comparing unrelated donor bone marrow transplantation with immunosuppressive therapy in severe aplastic anemia, and a natural history study of acquired and inherited bone marrow failure syndromes. The packet does not show that these studies enroll people with the TERC-related condition specifically. A trial title indicates the topic under study and does not establish an intervention's effect.